U.S. markets closed

Celyad to Present Data at 24th Congress of the European Hematology Association

MONT-SAINT-GUIBERT, Belgium, May 16, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced the selection of three abstracts for poster presentation at the upcoming 24th Congress of the European Hematology Association (EHA) in Amsterdam, The Netherlands, on June 13-16, 2019, including updated data from the THINK and DEPLETHINK Phase 1 trials evaluating the company’s autologous NKG2D-based CAR-T therapy CYAD-01 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndrome (MDS).

Clinical Presentation                   

Title:    Updated Results from the Phase 1 Trials Assessing a NKG2D CAR T-Cell Approach in Relapsed/Refractory Acute Myeloid Leukimia and Myelodysplastic Syndrome Patients
Abstract:    PS1212
Session:   Gene therapy, cellular immunotherapy and vaccination – Clinical
Date:    Saturday, June 15th
Time:    5:30 - 7:00 p.m. CEST (Poster Area)

Preclinical Presentations

Title:    Development of a Next Generation Allogeneic CAR-T Cell Platform Without Gene Editing
Abstract:   PS1210
Session:    Gene therapy, cellular immunotherapy and vaccination – Biology & Translational Research
Date:   Saturday, June 15th 
Elevator pitch:   4:30 - 4:45 p.m. CEST (Hall G106)
Time:    5:30 - 7:00 p.m. CEST (Poster Area)

Title:    Modeling NKG2D-based CAR-T Cell Therapy in Animals with Acute Myeloid Leukemia
Abstract:    PS974
Session:   Acute myeloid leukemia - Biology & Translational Research 
Date:    Saturday, June 15th 
Time:    5:30 - 7:00 p.m. CEST (Poster Area)

About Celyad

Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based product candidates and utilizes its expertise in cell engineering to target cancer. Celyad’s CAR-T cell platform has the potential to treat a broad range of solid and hematologic tumors. The company’s lead clinical candidate, CYAD-01, an autologous NKG2D-based CAR-T therapy, is currently being evaluated in several Phase 1 clinical trials to assess safety and clinical activity for the treatment of hematological malignancies, such as acute myeloid leukemia, and solid cancers, such as metastatic colorectal cancer. Celyad is also developing CYAD-101, an investigational, non-gene edited, allogeneic (donor derived) NKG2D-based CAR-T therapy, which is currently being evaluated in a Phase 1 trial for the treatment of patients with metastatic colorectal cancer. Celyad was founded in 2007 and is based in Mont-Saint-Guibert, Belgium, and New York, NY. Celyad’s ordinary shares are listed on the Euronext Brussels and Euronext Paris exchanges, and its American Depository Shares are listed on the Nasdaq Global Market, all under the ticker symbol CYAD.

For more information, please contact:

Filippo Petti, Chief Executive Officerinvestors@celyad.com 
Anne Moore, Vice President Corporate Strategy – T: +32(0) 10 39 41 87 – communications@celyad.com 
Belgique : Comfi
Laure-Eve Monfort – T.: +32 (0)2 290 90 93 – celyad@comfi.be 
For France: Ulysse Communication
Bruno Arabian – T.: +33 (0)6 87 88 47 26 – barabian@ulysse-communication.com 
U.S.: LifeSci Advisors
Relations Investisseurs : Daniel Ferry – T.: +1 (617) 535 7746 – daniel@lifesciadvisors.com 
Relations Publiques : Sara Zelkovic – T:+1 (646) 876 4933 – sara@lifescipublicrelations.com 

Forward-looking statements

This release may contain forward-looking statements, including statements regarding the safety and efficacy of CYAD-01 and CYAD-101; the ongoing and planned clinical development of CYAD-01 and CYAD-101, including the timing of trials, enrollment, data readouts and presentations; the clinical and commercial potential of CYAD-01 and CYAD-101 and the adequacy of Celyad’s financial resources; Celyad’s worldwide development and commercialization rights to CYAD-101; the ongoing and planned clinical and commercial potential and development of its shRNA technology; Celyad’s financial condition, results of operation and business outlook; and the planned presentation of clinical data at the 24th Congress of the European Hematology Association (EHA). Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual results, financial condition and liquidity, performance or achievements of Celyad, or industry results, to differ materially from those expressed or implied by such forward-looking statements. In particular it should be noted that the data summarized above are preliminary in nature. There is limited data concerning safety and clinical activity following treatment with the CYAD-01 and CYAD-101 drug product candidates. These results may not be repeated or observed in ongoing or future studies involving the CYAD-01 and CYAD-101 drug product candidates. These forward-looking statements are further qualified by important factors and risks, which could cause actual results to differ materially from those in the forward-looking statements, including statements about: the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our ability to advance drug product candidates into, and successfully complete, clinical trials; our ability to successfully manufacture drug product for our clinical trials, including with our mAb manufacturing process and with respect to manufacturing drug product with the desired number of T cells under our clinical trial protocols; our reliance on the success of our drug product candidates, including our dependence on the regulatory approval of CYAD-01 and CYAD-101 in the United States and Europe and subsequent commercial success of CYAD-01 and CYAD-101, both of which may never occur; the timing or likelihood of regulatory filings and approvals; our ability to develop sales and marketing capabilities; the commercialization of our drug product candidates, if approved; the pricing and reimbursement of our drug product candidates, if approved; the implementation of our business model, strategic plans for our business, drug product candidates and technology; the scope of protection we are able to establish and maintain for intellectual property rights covering our drug product candidates and technology; our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights and proprietary technology of third parties; cost associated with enforcing or defending intellectual property infringement, misappropriation or violation; product liability; and other claims; regulatory development in the United States, the European Union, and other jurisdictions; estimates of our expenses, future revenues, capital requirements and our needs for additional financing; the potential benefits of strategic collaboration agreements and our ability to maintain and enter into strategic arrangements; our ability to maintain and establish collaborations or obtain additional grant funding; the rate and degree of market acceptance of our drug product candidates, if approved; our financial performance; developments relating to our competitors and our industry, including competing therapies and statements regarding future revenue, hiring plans, expenses, capital expenditures, capital requirements and share performance. A further list and description of these risks, uncertainties and other risks can be found in Celyad’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in its Annual Report on Form 20-F filed with the SEC on April 5, 2019 and subsequent filings and reports by Celyad. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document and Celyad’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.